Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
about
Application of the Fc fusion format to generate tag-free bi-specific diabodies.Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody.Identification of an antibody fragment specific for androgen-dependent prostate cancer cells.Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasCytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokineticsAnti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-lifeTargeting T cells with bispecific antibodies for cancer therapyHexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity.Enhancement of sialylation on humanized IgG-like bispecific antibody by overexpression of α2,6-sialyltransferase derived from Chinese hamster ovary cells.Targeted cell-cell interactions by DNA nanoscaffold-templated multivalent bispecific aptamers.Multimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers.Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.A semi high-throughput method for screening small bispecific antibodies with high cytotoxicityEnhanced production of functional extracellular single chain variable fragment against HIV-1 matrix protein from Escherichia coli by sequential simplex optimization.The making of bispecific antibodiesT cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Affinity maturation of humanized anti-epidermal growth factor receptor antibody using a modified phage-based open sandwich selection method.Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity.
P2860
Q33518858-5C410CDC-4365-4640-929E-A790CFBB8755Q33966937-0DA2C388-796C-408F-9890-2A1B2D7E44C0Q33966998-F0FC3216-9AE0-4E6C-9F2D-51E8811409B9Q34152258-9EB166DB-96D8-484C-B6CC-C06B2423FC18Q34369841-4FDA4266-FC39-4011-A693-44844A0545E2Q34503084-FAF954BD-96C8-4EF8-8406-37A3525E5ACAQ36216009-6C66D82C-1CCC-4251-985A-A6CBFD2BA315Q36953914-1FA3BDF6-9302-4D9D-AA38-AB984348886FQ37220742-CADB75BB-7323-4E2E-8937-BAFE412D5DF6Q37234627-7ECAE53D-C449-418C-9240-39F6AD7EDA49Q37965555-03FB7916-4D04-40AE-BEF7-AF91B220909DQ38329171-BF11C08A-7D63-4509-8D84-042454993A90Q38335450-3FD9F6FC-8E5C-450F-A2E9-1607EAC71641Q39119871-35F3CE5B-C7BD-4F57-A616-6AEAF401D811Q39753915-222F48B7-E540-4E43-8CA6-99B4C74DA3F5Q42128614-2705D079-19AC-4960-955C-98C5A3CA5318Q42215470-9CD942B2-4122-443C-8EED-20990A94489EQ42323236-E969F741-FFAC-40A0-8FFE-4D225C825BCFQ47570404-E7744136-BC84-47CE-B462-323E52B839F5Q52608921-99BEC3DE-784A-4BF9-8471-EF51D61860EFQ52641571-44A22FD2-BC5C-4EBC-942B-CA38756F2A05
P2860
Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Highly effective recombinant f ...... of lymphocytes to tumor cells.
@en
type
label
Highly effective recombinant f ...... of lymphocytes to tumor cells.
@en
prefLabel
Highly effective recombinant f ...... of lymphocytes to tumor cells.
@en
P2093
P2860
P356
P1476
Highly effective recombinant f ...... of lymphocytes to tumor cells.
@en
P2093
Hidesuke Fukazawa
Hiroki Hayashi
Hiroko Kawaguchi
Izumi Kumagai
Michiaki Unno
Mitsuo Umetsu
Ryutaro Asano
Takeshi Nakanishi
Toshio Kudo
Yasuhiro Watanabe
P2860
P304
27659-27665
P356
10.1074/JBC.M704719200
P407
P577
2007-07-19T00:00:00Z